NCT01690221已完成3 期
A Phase 3B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Treatment Group, Multicenter Efficacy and Safety Study of Topical Diltiazem Hydrochloride 2% Cream in Subjects With Anal Fissure
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 434
- 试验地点
- 100
- 主要终点
- Change from baseline (average NRS during the last 3 days in which subject had a defecation during the 7 day screening period) in average of worst AF-related pain associated with or following defecation for Days 22-28 (Week 4).
研究概览
简要总结
The purpose of this study is to determine if the study drug, VEN307 (diltiazem hydrochloride cream) is safe and to see if it will help with treatment of pain associated with anal fissures.
详细描述
Primary Objective:
To evaluate the efficacy of diltiazem hydrochloride cream on reduction of worst anal fissure (AF)-related pain associated with or following defecation when administered three times a day (TID) for 28 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males or females, aged ≥ 18 to ≤ 75 years.
- •Subjects with evidence of a circumscribed fissure, with induration at the edges.
- •Subjects with AF-related pain associated with or following defecation occurring at least 2 times a week for at least 28 days prior to signing the informed consent form (ICF).
- •AF-related pain associated with or following defecation of at least 5 on an 11-point numerical rating score scale (NRS) at the last defecation prior to signing the ICF (0 being no pain; 10 being the worst possible pain).
- •Average AF-related pain associated with or following defecation of at least 5 on an 11-point NRS during the last 3 days in which subject had a defecation during the 7 days prior to randomization.
- •Any female of non-childbearing potential, including any female who: a) has had a hysterectomy, b) has had a bilateral oophorectomy, c) has had a bilateral tubal ligation or d) is post menopausal (demonstration of total cessation of menses for ≥ 1 year from the date of screening visit).
- •Females of child bearing potential who agree to use at least one form of contraception (may be a barrier method), during the full duration of the study.
- •Able to communicate adequately with the investigator and to comply with the requirements for the entire study.
- •Capable of using the IVRS and able to adequately communicate comprehension of the IVRS questions to the investigator.
- •Capable of and freely willing to provide written informed consent prior to participating in the study.
排除标准
- •Unwilling to have visual or medical examination of the AF.
- •More than 1 AF.
- •Subjects with AF associated with or caused by other conditions, including but not limited to: drug-induced, trauma, HIV infection, fistula-in-ano, inflammatory bowel disease, perianal sepsis or malignancy.
- •Unwilling to stop all other concomitant topical preparations applied in and around the anus from signing of ICF through Day 29 of the study.
- •Use of glyceryl trinitrate (GTN) ointment for 7 days (continuous or not) in the 28 days prior to signing the ICF.
- •Unwilling to discontinue use of sitz baths for up to 4 hours after each application of investigational product from signing of ICF to end of study.
- •Unwilling to discontinue use of anesthetics from signing the ICF to end of study.
- •Subfissure injection of botulinum toxin in the 3 months prior to signing the ICF.
- •Known sensitivity to investigational product(s) or calcium channel blockers.
- •Previous treatment with diltiazem hydrochloride cream or any other topical calcium channel blockers.
- •Active treatment with anti-viral therapies for HIV (e.g. indinavir, nelfinivir, ritonavir).
- •Treatment with any of the following medications within 14 days prior to signing the ICF:
- •Amitriptyline
- •Benzodiazepines
- •β-adrenoceptor antagonists (Beta-Blockers)
- •Buspirone
- •Calcium channel blockers
- •Carbamazepine
- •Cimetidine
- •Cyclosporin
- •Investigational agents
- •Lovastatin
- •Pregabalin
- •Quinidine
- •Following concomitant disease state:
- •Sick sinus syndrome except in the presence of a functioning ventricular pacemaker.
- •Second-or third-degree AV block except in the presence of a functioning ventricular pacemaker.
- •Hypotension (less than 90 mm Hg systolic).
- •Acute myocardial infarction and pulmonary congestion documented by x-ray.
- •History of bipolar disorder, psychosis, schizophrenia, mania, suicide attempt or suicidal ideation, or any other significant psychiatric illness (with the exception of intermittent anxiety) per investigator judgment.
- •History of clinically significant renal disease per investigator judgment.
- •History of clinically significant Alzheimer's or Parkinson's disease per investigator judgment.
- •History of clinically significant hepatic disease per investigator judgment.
- •Current infection treated with a macrolide antibiotic.
- •Clinical evidence or history of fecal incontinence.
- •Clinical evidence or history of anal fistula.
- •Clinical evidence or history of anal abscess.
- •History of inflammatory bowel disease (e.g. Crohn's disease, Ulcerative Colitis).
- •History of any prior anal or rectal surgery including but not limited to: lateral sphincterotomy and anal stretch (with the exception of hemorrhoidal banding and laser surgery).
- •Grade 4 hemorrhoids.
- •Chronic constipation.
- •History of radiation therapy to the pelvis.
- •Fixed anal stenosis/fibrosis.
- •Major organ transplant.
- •Any clinically significant laboratory abnormalities during screening per investigator judgment.
- •Body Mass Index (BMI) > 40 kg/m2
- •Malignancy within 5 years prior to randomization (with the exception of treated basal cell/squamous cell carcinoma of the skin).
- •Any disease or prior/planned surgery that may interfere with the subject successfully completing the study.
- •Currently using narcotic(s).
- •Breast-feeding females.
- 另有 1 项未显示
研究组 & 干预措施
VEN 307
Experimental
diltiazem hydrochloride 2% cream
干预措施: VEN 307 (Drug)
Placebo
Placebo Comparator
Placebo Cream
干预措施: Placebo (Drug)
结局指标
主要结局
Change from baseline (average NRS during the last 3 days in which subject had a defecation during the 7 day screening period) in average of worst AF-related pain associated with or following defecation for Days 22-28 (Week 4).
时间窗: 28 days
次要结局
未报告次要终点
研究者
研究点 (100)
Loading locations...
相似试验
已完成
1 期
3VM for Treatment of Chronic Osteoarthritis Knee PainArthritis, DegenerativeNCT03142178CDA Research Group, Inc.150
终止
2 期
CT 327 in the Treatment of Atopic DermatitisMild to Moderate Atopic DermatitisNCT00996008Creabilis SA15
已完成
2 期
CT 327 in the Treatment of Psoriasis VulgarisPsoriasisNCT00995969Creabilis SA58
已完成
3 期
Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)Giant Cell Tumors of the Tendon SheathTenosynovial Giant Cell TumorPigmented Villonodular SynovitisNCT02371369Daiichi Sankyo120
已完成
2 期
A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic PainPainDiabetic NeuropathiesNCT00375960Vernalis (R&D) Ltd50